FDA Adverse Event Injury Summary report: N

THERASPHERE Y-90 (10 GBQ) CN CLINICAL

MDR report key: 20363981 · Received October 3, 2024

Report

Report Number
2124215-2024-61889
Event Type
Injury
Date Received
October 3, 2024
Date of Event
July 21, 2024
Report Date
October 3, 2024
Manufacturer
BIOCOMPATIBLES UK LIMITED
Product Code
NAW
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
CH
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

A2 - AGE AT TIME OF EVENT: THE SUBJECT WAS 43 YEARS OLD AT THE TIME OF STUDY ENROLLMENT. D3 & G1 - MANUFACTURER ADDRESS 1: (B)(6). D3 & G1 - MANUFACTURER ZIP/POSTAL CODE: (B)(6).

Description of Event or Problem · 0

(B)(4) CLINICAL STUDY. IT WAS REPORTED THAT AS A RESULT OF THERASPHERE ADMINISTRATION, THE SUBJECT DEVELOPED AN INTESTINAL OBSTRUCTION AND WAS TREATED WITH PRESCRIPTION MEDICATION. ON (B)(6) 2024, THE SUBJECT WAS RANDOMIZED IN THE THERASPHERE ARM OF THE (B)(4) STUDY. TREATMENT WITH THERASPHERE WAS PERFORMED ON (B)(6) 2024. 99MTC-MAA ANGIOGRAM WAS PERFORMED, AND TARGET VOLUME WAS (B)(4). (B)(4) VIALS OF THERASPHERE WERE ADMINISTERED. (B)(4) GBQ WAS ADMINISTERED THROUGH VIAL (B)(4) (LOT # 2499330), (B)(4) GBQ WAS ADMINISTERED THROUGH VIAL (B)(4) (LOT # 2499324), AND (B)(4) GBQ WAS ADMINISTERED THROUGH VIAL (B)(4) (LOT # 2499328). A TOTAL OF (B)(4) GBQ WAS ADMINISTERED. TOTAL ACTIVITY OF THERASPHERE DELIVERY TO LUNG WAS REPORTED AS(B)(4) GBQ, THERASPHERE DELIVERY TO PERFUSED LIVER TISSUE WAS (B)(4) GY, AND DOSE TO PERFUSED TARGET TUMOR TISSUE WAS (B)(4) GY. ON (B)(6) 2024, (B)(4) DAYS POST INDEX PROCEDURE, THE SUBJECT EXPERIENCED VENTOSITY (FLATULENCE) AND ASTRICTION (INTESTINAL OBSTRUCTION). NO CORRECTIVE ACTION WAS TAKEN TO TREAT THE VENTOSITY. ASTRICTION WAS TREATED MEDICALLY USING A GLYCERIN ENEMA AND LACTULOSE ORAL SOLUTION.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1267526 THERASPHERE Y-90 (10 GBQ) CN CLINICAL MICROSPHERES RADIONUCLIDE NAW BIOCOMPATIBLES UK LIMITED 2361-01 2499328

Patients

Seq Age Sex Outcome Treatment
1 43 YR Male Required Intervention